US FDA approves Eli Lilly’s drug for eczema

hanuman

Active member
usfda-approved-black.jpg

Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old.​

The drug, which is an injectable medicine and branded Ebglyss, will be available in the next few weeks, the company said.​

Eczema, also known as atopic dermatitis, is an inflammatory skin condition that can cause itching, rashes and dry patches.​

The FDA’s approval was based on three studies involving over 1,000 patients with moderate-to-severe eczema who were unable to control their symptoms with topical medicines or other systemic treatments, Eli Lilly said.​

Last year, the regulator had declined to approve the drug due to certain findings during an inspection of a contract manufacturer.​

Nearly 16.5 million adults in the U.S. have eczema, according to the National Eczema Association.​

Eczema has multiple treatments available, including AbbVie’s Rinvoq, Pfizer’s Cibinqo, Sanofi, and Regeneron’s Dupixent as well as some generic drugs such as cetirizine.​

Unlike Dupixent, which has to be dosed twice a month for adults, Ebglyss can be dosed once-monthly, which is “viewed as attractive by experts and likely also patients,” Jefferies analyst Lucy Codrington wrote in a note last year.​

The drug is already approved for use in Europe and Japan, with additional markets expected later this year, the company said.​

Ebglyss is a monoclonal antibody that selectively targets and neutralizes the IL-13 protein that causes progression of eczema.​


The post appeared first on .
 
Top
AdBlock Detected

We get it, advertisements are annoying!

Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.

I've Disabled AdBlock